NeuroPharm study: EEG wakefulness regulation as a biomarker in MDD

Publikation: Bidrag til tidsskriftTidsskriftartikelfagfællebedømt

Standard

NeuroPharm study : EEG wakefulness regulation as a biomarker in MDD. / Ip, Cheng Teng; Ganz, Melanie; Dam, Vibeke H.; Ozenne, Brice; Rüesch, Annia; Köhler-Forsberg, Kristin; Jørgensen, Martin B.; Frokjaer, Vibe G.; Søgaard, Birgitte; Christensen, Søren R.; Knudsen, Gitte M.; Olbrich, Sebastian.

I: Journal of Psychiatric Research, Bind 141, 2021, s. 57-65.

Publikation: Bidrag til tidsskriftTidsskriftartikelfagfællebedømt

Harvard

Ip, CT, Ganz, M, Dam, VH, Ozenne, B, Rüesch, A, Köhler-Forsberg, K, Jørgensen, MB, Frokjaer, VG, Søgaard, B, Christensen, SR, Knudsen, GM & Olbrich, S 2021, 'NeuroPharm study: EEG wakefulness regulation as a biomarker in MDD', Journal of Psychiatric Research, bind 141, s. 57-65. https://doi.org/10.1016/j.jpsychires.2021.06.021

APA

Ip, C. T., Ganz, M., Dam, V. H., Ozenne, B., Rüesch, A., Köhler-Forsberg, K., Jørgensen, M. B., Frokjaer, V. G., Søgaard, B., Christensen, S. R., Knudsen, G. M., & Olbrich, S. (2021). NeuroPharm study: EEG wakefulness regulation as a biomarker in MDD. Journal of Psychiatric Research, 141, 57-65. https://doi.org/10.1016/j.jpsychires.2021.06.021

Vancouver

Ip CT, Ganz M, Dam VH, Ozenne B, Rüesch A, Köhler-Forsberg K o.a. NeuroPharm study: EEG wakefulness regulation as a biomarker in MDD. Journal of Psychiatric Research. 2021;141:57-65. https://doi.org/10.1016/j.jpsychires.2021.06.021

Author

Ip, Cheng Teng ; Ganz, Melanie ; Dam, Vibeke H. ; Ozenne, Brice ; Rüesch, Annia ; Köhler-Forsberg, Kristin ; Jørgensen, Martin B. ; Frokjaer, Vibe G. ; Søgaard, Birgitte ; Christensen, Søren R. ; Knudsen, Gitte M. ; Olbrich, Sebastian. / NeuroPharm study : EEG wakefulness regulation as a biomarker in MDD. I: Journal of Psychiatric Research. 2021 ; Bind 141. s. 57-65.

Bibtex

@article{2fe8cc31db3c47a99fcdfc0f15bdbb86,
title = "NeuroPharm study: EEG wakefulness regulation as a biomarker in MDD",
abstract = "While several electroencephalogram (EEG)-based biomarkers have been proposed as diagnostic or predictive tools in major depressive disorder (MDD), there is a clear lack of replication studies in this field. Markers that link clinical features such as disturbed wakefulness regulation in MDD with neurophysiological patterns are particularly promising candidates for e.g., EEG-informed choices of antidepressive treatment. We investigate if we in an independent MDD sample can replicate abnormal findings of EEG-vigilance regulation during rest and as a predictor for antidepressive treatment response. EEG-resting state was recorded in 91 patients and 35 healthy controls from the NeuroPharm trial. EEG-vigilance was assessed using the Vigilance Algorithm Leipzig (VIGALL). We compared the vigilance regulation during rest between patients and healthy controls and between remitters/responders and non-remitters/non-responders after eight weeks of SSRI/SNRI treatment using two different sets of response criteria (NeuroPharm and iSPOT-D). We replicated previous findings showing hyperstable EEG-wakefulness regulation in patients in comparison to healthy subjects. Responders defined by the iSPOT-D criteria showed a higher propensity toward low vigilance stages in comparison to patients with no response at pretreatment, however, this did not apply when using the NeuroPharm criteria. EEG-wakefulness regulation patterns normalized toward patterns of healthy controls after 8 weeks of treatment. This replication study supports the diagnostic value of EEG-vigilance regulation and its usefulness as a biomarker for the choice of treatment in MDD.",
keywords = "Antidepressant treatment effect, Biomarker, EEG, MDD, SSRI, VIGALL",
author = "Ip, {Cheng Teng} and Melanie Ganz and Dam, {Vibeke H.} and Brice Ozenne and Annia R{\"u}esch and Kristin K{\"o}hler-Forsberg and J{\o}rgensen, {Martin B.} and Frokjaer, {Vibe G.} and Birgitte S{\o}gaard and Christensen, {S{\o}ren R.} and Knudsen, {Gitte M.} and Sebastian Olbrich",
note = "Funding Information: Collection of the data included in the study was supported by Innovationsfonden, Denmark (4108-00004B) and by the Lundbeck Foundation (Cimbi: R90-A7722). C.I. was supported by the Innovationsfonden, Denmark (5189-00087A). M.G. was supported by the Lundbeck Foundation (R181-2014-3586) and the Elsass foundation (18-3-0147). V.D. was supported by Augustinus Foundation (16-0058) and Rigshospitalet's Research (R149-A6325). M.J. was supported by Savv?rksejer Jeppe Juhl og hustru Ovita Juhls Mindelegat. V.F. was supported by Augustinus Foundation (16-0058). G.K. was supported by Innovationsfonden, Denmark (4108-00004B) Funding Information: Collection of the data included in the study was supported by Innovationsfonden , Denmark ( 4108-00004B ) and by the Lundbeck Foundation (Cimbi: R90-A7722 ). C.I. was supported by the Innovationsfonden , Denmark ( 5189-00087A ). M.G. was supported by the Lundbeck Foundation ( R181-2014-3586 ) and the Elsass foundation ( 18-3-0147 ). V.D. was supported by Augustinus Foundation ( 16-0058 ) and Rigshospitalet{\textquoteright}s Research ( R149-A6325 ). M.J. was supported by Savv{\ae}rksejer Jeppe Juhl og hustru Ovita Juhls Mindelegat . V.F. was supported by Augustinus Foundation ( 16-0058 ). G.K. was supported by Innovationsfonden , Denmark ( 4108-00004B ) Publisher Copyright: {\textcopyright} 2021 The Authors",
year = "2021",
doi = "10.1016/j.jpsychires.2021.06.021",
language = "English",
volume = "141",
pages = "57--65",
journal = "Journal of Psychiatric Research",
issn = "0022-3956",
publisher = "Pergamon Press",

}

RIS

TY - JOUR

T1 - NeuroPharm study

T2 - EEG wakefulness regulation as a biomarker in MDD

AU - Ip, Cheng Teng

AU - Ganz, Melanie

AU - Dam, Vibeke H.

AU - Ozenne, Brice

AU - Rüesch, Annia

AU - Köhler-Forsberg, Kristin

AU - Jørgensen, Martin B.

AU - Frokjaer, Vibe G.

AU - Søgaard, Birgitte

AU - Christensen, Søren R.

AU - Knudsen, Gitte M.

AU - Olbrich, Sebastian

N1 - Funding Information: Collection of the data included in the study was supported by Innovationsfonden, Denmark (4108-00004B) and by the Lundbeck Foundation (Cimbi: R90-A7722). C.I. was supported by the Innovationsfonden, Denmark (5189-00087A). M.G. was supported by the Lundbeck Foundation (R181-2014-3586) and the Elsass foundation (18-3-0147). V.D. was supported by Augustinus Foundation (16-0058) and Rigshospitalet's Research (R149-A6325). M.J. was supported by Savv?rksejer Jeppe Juhl og hustru Ovita Juhls Mindelegat. V.F. was supported by Augustinus Foundation (16-0058). G.K. was supported by Innovationsfonden, Denmark (4108-00004B) Funding Information: Collection of the data included in the study was supported by Innovationsfonden , Denmark ( 4108-00004B ) and by the Lundbeck Foundation (Cimbi: R90-A7722 ). C.I. was supported by the Innovationsfonden , Denmark ( 5189-00087A ). M.G. was supported by the Lundbeck Foundation ( R181-2014-3586 ) and the Elsass foundation ( 18-3-0147 ). V.D. was supported by Augustinus Foundation ( 16-0058 ) and Rigshospitalet’s Research ( R149-A6325 ). M.J. was supported by Savværksejer Jeppe Juhl og hustru Ovita Juhls Mindelegat . V.F. was supported by Augustinus Foundation ( 16-0058 ). G.K. was supported by Innovationsfonden , Denmark ( 4108-00004B ) Publisher Copyright: © 2021 The Authors

PY - 2021

Y1 - 2021

N2 - While several electroencephalogram (EEG)-based biomarkers have been proposed as diagnostic or predictive tools in major depressive disorder (MDD), there is a clear lack of replication studies in this field. Markers that link clinical features such as disturbed wakefulness regulation in MDD with neurophysiological patterns are particularly promising candidates for e.g., EEG-informed choices of antidepressive treatment. We investigate if we in an independent MDD sample can replicate abnormal findings of EEG-vigilance regulation during rest and as a predictor for antidepressive treatment response. EEG-resting state was recorded in 91 patients and 35 healthy controls from the NeuroPharm trial. EEG-vigilance was assessed using the Vigilance Algorithm Leipzig (VIGALL). We compared the vigilance regulation during rest between patients and healthy controls and between remitters/responders and non-remitters/non-responders after eight weeks of SSRI/SNRI treatment using two different sets of response criteria (NeuroPharm and iSPOT-D). We replicated previous findings showing hyperstable EEG-wakefulness regulation in patients in comparison to healthy subjects. Responders defined by the iSPOT-D criteria showed a higher propensity toward low vigilance stages in comparison to patients with no response at pretreatment, however, this did not apply when using the NeuroPharm criteria. EEG-wakefulness regulation patterns normalized toward patterns of healthy controls after 8 weeks of treatment. This replication study supports the diagnostic value of EEG-vigilance regulation and its usefulness as a biomarker for the choice of treatment in MDD.

AB - While several electroencephalogram (EEG)-based biomarkers have been proposed as diagnostic or predictive tools in major depressive disorder (MDD), there is a clear lack of replication studies in this field. Markers that link clinical features such as disturbed wakefulness regulation in MDD with neurophysiological patterns are particularly promising candidates for e.g., EEG-informed choices of antidepressive treatment. We investigate if we in an independent MDD sample can replicate abnormal findings of EEG-vigilance regulation during rest and as a predictor for antidepressive treatment response. EEG-resting state was recorded in 91 patients and 35 healthy controls from the NeuroPharm trial. EEG-vigilance was assessed using the Vigilance Algorithm Leipzig (VIGALL). We compared the vigilance regulation during rest between patients and healthy controls and between remitters/responders and non-remitters/non-responders after eight weeks of SSRI/SNRI treatment using two different sets of response criteria (NeuroPharm and iSPOT-D). We replicated previous findings showing hyperstable EEG-wakefulness regulation in patients in comparison to healthy subjects. Responders defined by the iSPOT-D criteria showed a higher propensity toward low vigilance stages in comparison to patients with no response at pretreatment, however, this did not apply when using the NeuroPharm criteria. EEG-wakefulness regulation patterns normalized toward patterns of healthy controls after 8 weeks of treatment. This replication study supports the diagnostic value of EEG-vigilance regulation and its usefulness as a biomarker for the choice of treatment in MDD.

KW - Antidepressant treatment effect

KW - Biomarker

KW - EEG

KW - MDD

KW - SSRI

KW - VIGALL

U2 - 10.1016/j.jpsychires.2021.06.021

DO - 10.1016/j.jpsychires.2021.06.021

M3 - Journal article

C2 - 34175743

AN - SCOPUS:85108414197

VL - 141

SP - 57

EP - 65

JO - Journal of Psychiatric Research

JF - Journal of Psychiatric Research

SN - 0022-3956

ER -

ID: 273136370